National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
P01AI167966
米国
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
DP1AI158186
米国
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
75N93022C00036
米国
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
S10OD032290
米国
Burroughs Wellcome Fund
米国
Howard Hughes Medical Institute (HHMI)
米国
引用
ジャーナル: Immunity / 年: 2024 タイトル: Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses. 著者: Megi Rexhepaj / Daniel Asarnow / Lisa Perruzza / Young-Jun Park / Barbara Guarino / Mathew Mccallum / Katja Culap / Christian Saliba / Giada Leoni / Alessio Balmelli / Courtney N Yoshiyama / ...著者: Megi Rexhepaj / Daniel Asarnow / Lisa Perruzza / Young-Jun Park / Barbara Guarino / Mathew Mccallum / Katja Culap / Christian Saliba / Giada Leoni / Alessio Balmelli / Courtney N Yoshiyama / Miles S Dickinson / Joel Quispe / Jack T Brown / M Alejandra Tortorici / Kaitlin R Sprouse / Ashley L Taylor / Davide Corti / Tyler N Starr / Fabio Benigni / David Veesler / 要旨: Porcine delta-coronavirus (PDCoV) spillovers were recently detected in febrile children, underscoring the recurrent zoonoses of divergent CoVs. To date, no vaccines or specific therapeutics are ...Porcine delta-coronavirus (PDCoV) spillovers were recently detected in febrile children, underscoring the recurrent zoonoses of divergent CoVs. To date, no vaccines or specific therapeutics are approved for use in humans against PDCoV. To prepare for possible future PDCoV epidemics, we isolated PDCoV spike (S)-directed monoclonal antibodies (mAbs) from humanized mice and found that two, designated PD33 and PD41, broadly neutralized a panel of PDCoV variants. Cryoelectron microscopy (cryo-EM) structures of PD33 and PD41 in complex with the S receptor-binding domain (RBD) and ectodomain trimer revealed the epitopes recognized by these mAbs, rationalizing their broad inhibitory activity. We show that both mAbs competitively interfere with host aminopeptidase N binding to neutralize PDCoV and used deep-mutational scanning epitope mapping to associate RBD antigenic sites with mAb-mediated neutralization potency. Our results indicate a PD33-PD41 mAb cocktail may heighten the barrier to escape. PD33 and PD41 are candidates for clinical advancement against future PDCoV outbreaks.